Drugs / Dypirone
Trials 0
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01182974 Comparator | Aug 2010 → Aug 2011 | infectious disease with sepsis | Barzilai Medical Center | Suspended | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03529097 Comparator | Jun 2018 → Dec 2019 | urinary tract obstruction | Sheba Medical Center | Withdrawn | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04148846 Background | Sep 2019 → Sep 2020 | headache disorder | University of Sao Paulo General Hospital | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dypirone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01182974 ↗ |
| Known as | Optalgin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03529097 ↗ |
| Route | Intramuscular | “1 gr PO/PZ/PR/IM” NCT01182974 ↗ |
| Route | Oral | “1 gr PO/PZ/PR/IM” NCT01182974 ↗ |
| Route | Rectal | “1 gr PO/PZ/PR/IM” NCT01182974 ↗ |